Welcome to our dedicated page for Pmv Pharmaceuticals news (Ticker: PMVP), a resource for investors and traders seeking the latest updates and insights on Pmv Pharmaceuticals stock.
PMV Pharmaceuticals, Inc. (PMVP) is a clinical-stage biopharmaceutical company pioneering precision oncology therapies targeting p53 mutations, a key driver in many cancers. This page provides investors and researchers with verified updates on clinical trials, regulatory milestones, and corporate developments.
Access real-time announcements including phase progressions for PC14586 and other pipeline candidates, financial disclosures, and strategic collaborations. Our curated repository ensures you stay informed about PMVP’s tumor-agnostic approach to reactivating p53’s tumor-suppressing function.
Key updates cover clinical data publications, FDA designations, and research partnerships advancing small-molecule therapeutics. Bookmark this page for streamlined access to PMVP’s progress in developing treatments that address unmet needs in genetically defined cancers.
PMV Pharmaceuticals (Nasdaq: PMVP) reported third-quarter 2025 results and clinical updates on rezatapopt from the Phase 2 pivotal PYNNACLE study presented at the 2025 AACR-NCI-EORTC conference on October 24, 2025.
Key clinical data: 34% ORR (35/103) across evaluable patients, 46% ORR in the ovarian cohort (22/48) with one confirmed complete response and median duration of response of 8.0 months in ovarian patients. Median time to response across cohorts was 1.3 months. The company plans an NDA submission for platinum-resistant/refractory ovarian cancer in Q1 2027.
Financials: cash, equivalents, and marketable securities of $129.3M as of September 30, 2025, providing expected runway to end of Q1 2027. Net cash used in operations was $56.4M for the nine months ended September 30, 2025.
PMV Pharmaceuticals (Nasdaq: PMVP) reported updated Phase 2 PYNNACLE monotherapy data for rezatapopt (TP53 Y220C) with a 34% ORR across 103 evaluable patients and median duration of response of 7.6 months (data cutoff Sept 4, 2025). Confirmed responses appeared in eight tumor types including ovarian, lung, breast, endometrial, head and neck, colorectal, gallbladder, and ampullary cancer.
The ovarian cohort showed a 46% ORR (22/48) with median duration of response 8.0 months. Safety was mostly Grade 1–2; Grade 3 TRAEs ≤6% and drug discontinuations due to TRAEs were 3.6%. An NDA for platinum-resistant/refractory ovarian cancer is planned for Q1 2027.
PMV Pharmaceuticals (NASDAQ: PMVP) will present initial clinical data for rezatapopt at the AACR-NCI-EORTC conference in Boston on October 22–26, 2025. An oral presentation will report an initial analysis of the pivotal PYNNACLE Phase 2 trial in patients with locally advanced or metastatic solid tumors harboring a TP53 Y220C mutation on Friday, October 24 at 10:00–11:40 AM ET, presented by Dr. Alison M. Schram.
Two poster presentations will follow: the PYNNACLE initial analysis on Friday, October 24 (12:30–4:00 PM ET, Poster Session B, Exhibit Hall D) and a real-world natural history and prognostic study of TP53 Y220C on Saturday, October 25 (12:30–4:00 PM ET, Poster Session C, Exhibit Hall D).
PMV Pharmaceuticals (NASDAQ:PMVP) announced promising interim data from its Phase 2 PYNNACLE trial evaluating rezatapopt in patients with TP53 Y220C-mutated advanced solid tumors. The trial demonstrated a 33% overall response rate (ORR) across 97 evaluable patients, with confirmed responses in eight different tumor types.
Key highlights include a 43% ORR in ovarian cancer patients with 7.6 months median duration of response. The safety profile showed mostly Grade 1-2 treatment-related adverse events, with a low 3.7% discontinuation rate. Following FDA feedback, PMV plans to enroll an additional 20-25 platinum resistant/refractory ovarian cancer patients and submit a New Drug Application (NDA) in Q1 2027.
PMV Pharmaceuticals (NASDAQ:PMVP), a precision oncology company, has announced its Q2 2025 financial results and will host an investor webinar on September 10, 2025 to review interim analysis data from the Phase 2 PYNNACLE clinical trial. The analysis will include data from approximately 65 patients with at least 18 weeks of follow-up, with about 45% in the ovarian cancer cohort.
The company reported $148.3 million in cash and equivalents as of June 30, 2025, providing runway through 2026. Q2 2025 net loss was $21.2 million, compared to $1.2 million in Q2 2024. R&D expenses increased to $18.4 million, while G&A expenses decreased to $4.5 million.
PMV Pharmaceuticals (PMVP), a precision oncology company focused on developing small molecule, tumor-agnostic therapies targeting p53, has announced its participation in two upcoming investor conferences. The company's management, including CEO David H. Mack and Chief Development Officer Deepika Jalota, will present at the TD Cowen 6th Annual Oncology Innovation Summit on May 27, 2025, at 11:30 AM EDT, and the Jefferies Global Healthcare Conference on June 5, 2025, at 3:45 PM EDT. Both presentations will be available via live audio webcast, with replays accessible for 90 days afterward.
PMV Pharmaceuticals (PMVP) has reported its Q1 2025 financial results and provided updates on its PYNNACLE clinical trial for rezatapopt. The company plans to release interim analysis data from approximately 50 patients in mid-2025, with 40% from the ovarian cancer cohort. Financially, PMV ended Q1 with $165.8 million in cash and equivalents, expecting runway through 2026.
The company reported a net loss of $17.5 million for Q1 2025, compared to $15.3 million in Q1 2024. R&D expenses increased to $17.4 million from $13.2 million year-over-year, while G&A expenses decreased to $4.1 million from $5.0 million. Net cash used in operations was $18.3 million for Q1 2025.
PMV Pharmaceuticals (PMVP) reported its full year 2024 financial results, highlighting progress in its PYNNACLE clinical trial for rezatapopt. The company ended 2024 with $183.3 million in cash and equivalents, providing runway through 2026.
Key developments include:
- Over 90% of sites activated for Phase 2 PYNNACLE trial across global regions
- Interim analysis data expected mid-2025
- New Phase 1b study launched with MD Anderson Cancer Center
- Net loss of $58.7 million in 2024, improved from $69.0 million in 2023
- R&D expenses increased to $58.5 million from $55.9 million
The PYNNACLE Phase 1 trial showed promising results with 7 confirmed partial responses in ovarian cancer patients and 3 in breast cancer patients. However, the company discontinued the combination arm with KEYTRUDA® due to insufficient clinical benefit.
PMV Pharmaceuticals (Nasdaq: PMVP), a precision oncology company focused on p53-targeting therapies, has announced its participation in two major upcoming investor conferences. David H. Mack, Ph.D., President and CEO, and Deepika Jalota, Pharm. D., Chief Development Officer, will represent the company.
The conferences include the Oppenheimer 35th Annual Healthcare Life Sciences Conference on February 12, 2025, at 12:40 PM EST, and the TD Cowen 45th Annual Health Care Conference on March 4, 2025, at 3:10 PM EST. Management will also conduct one-on-one investor meetings during these events.
Live audio webcasts will be available online, with archived replays accessible for 90 days following each presentation through the company's Events & Presentations platform.
PMV Pharmaceuticals reported Q3 2024 financial results and provided updates on its PYNNACLE clinical trial. The Phase 2 portion evaluating rezatapopt as monotherapy is progressing with over 75% of sites activated globally. The company ended Q3 with $197.9 million in cash, providing runway through 2026. Net loss increased to $19.2 million from $16.6 million year-over-year. R&D expenses rose to $16.9 million, while G&A expenses decreased to $4.9 million. The company plans an interim analysis by mid-2025 and anticipates a New Drug Application filing by end of 2026.
FAQ
What is the current stock price of Pmv Pharmaceuticals (PMVP)?
What is the market cap of Pmv Pharmaceuticals (PMVP)?
